Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

5.04314

Sigma-Aldrich

Bortezomib

≥98% (LC/MS), solid, 20S proteasome inhibitor, Calbiochem®

Sinónimos:

Bortezomib, (R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid, BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, PS341, Proteasome Inhibitor XXII, PS-341, MG-341, Pyz-Phe-boroLeu, BTZ, LDP-341, LDP341, MG341, MLN-341, MLN341, PS341, Proteasome Inhibitor XXII, PS-341, MG-341, Pyz-Phe-boroLeu, (R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C19H25BN4O4
Número de CAS:
179324-69-7
Peso molecular:
384.24
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Bortezomib,

assay

≥98% (LC/MS)

Quality Level

100

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated (hygroscopic)
protect from light

color

off-white

solubility

DMSO: 100 mg/mL
ethanol: 2 mg/mL (with sonication)

storage temp.

−20°C

InChI

1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1

InChI key

GXJABQQUPOEUTA-RDJZCZTQSA-N

General description

Bortezomib, a cell-permeable dipeptidylboronate compound, is a proteasome inhibitor. The proteasomal system is crucial for cellular protein turnover, which is necessary for maintaining cell homeostasis. Bortezomib binds reversibly to the chymotrypsin-like subunit of the 26S proteasome, inhibiting its function and thereby preventing the degradation of multiple pro-apoptotic factors. Bortezomib selectively inhibits 20S proteasome β5 ChTL/chymotrypsin- over β1 CL/caspase- and β2 TL/trypsin-like activity (kinact/Ki = 38,000, 5,700, and <100 M-1s-1, respectively, in human 20S proteasome assays using 10 M Suc-LLVY-AMC/Cat. No. 539142, 10 M Z-LLE-AMC/Cat. No. 539141, or 50 M Boc-LRR-AMC as substrate; IC50 in 1 h = 7, 74, and 4,200 nM, respectively) via a covalent, slowly reversible, interaction between the nucleophilic Thr1 hydroxy group/Thr1Oγ of the catalytic β subunit and the inhibitor′s electrophilic boronic moiety, displaying much reduced potency against human chymotrypsin, cathepsin G, leukocyte elastase, and thrombin (Ki = 0.32, 0.63, 2.3, and 13 M, respectively, vs. 620 nM using rabbit muscle 20S). A widely used inhibitor both in cultures in vitro and in animals in vivo. Despite being the first proteasome inhibitor approved by FDA for clinical anticancer treatment, its therapeutic efficacy continues to be hampered by off-target effects and dose-limiting toxicity.

Application

Bortezomib has been used to induce aerobic glycolysis/ neuropathic pain in mice and study chemotherapy-induced painful peripheral neuropathy.

Biochem/physiol Actions

Cell permeable: yes
Reversible: yes

Features and Benefits

  • Cell permeable and enables targeted action
  • Allows reversible modulation of cellular processes

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Preparation Note

Use only fresh DMSO or Ethanol for reconstitution.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C.) Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Du, X.L, and Chen, Q. 2013. Acta Haematol.129, 207.
Tamatani, T., et al. 2013. Int. J. Oncol.42, 935.
Beck, P., et al. 2012. J. Biol. Chem.393, 1101.
Fang, H.T., et al. 2012. Proc. Natl. Acad. Sci. USA.109, 2521.
Chen, D., et al. 2011. Curr. Cancer Drug Targets11, 239.
Demo, S.D., et al. 2007. Cancer Res.67, 6383.
Adams, J., et al. 1999. Cancer Res.59, 2615.
Teicher, B.A., et al. 1999. Clin. Cancer Res.5, 2638.
Adams, J., et al. 1998. Bioorg. Med. Chem. Lett.8, 333.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

D Chen et al.
Current cancer drug targets, 11(3), 239-253 (2011-01-21)
Targeting the ubiquitin-proteasome pathway has emerged as a rational approach in the treatment of human cancer. Based on positive preclinical and clinical studies, bortezomib was subsequently approved for the clinical use as a front-line treatment for newly diagnosed multiple myeloma
Philipp Beck et al.
Biological chemistry, 393(10), 1101-1120 (2012-10-24)
The 20S proteasome core particle (CP) is the proteolytically active key element of the ubiquitin proteasome system that directs the majority of intracellular protein degradation in eukaryotic cells. Over the past decade, the CP has emerged as an anticancer therapy
J Adams et al.
Cancer research, 59(11), 2615-2622 (1999-06-11)
The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth. Dysregulating the degradation of such proteins should have profound effects on tumor growth and cause cells to undergo apoptosis.
Tetsuya Tamatani et al.
International journal of oncology, 42(3), 935-944 (2013-01-24)
Oral cancer cells have a significantly augmented nuclear factor-κB (NF-κB) activity and the inhibition of this activity suppresses tumor growth. Bortezomib is a proteasome inhibitor and a drug used for molecular-targeted therapy (targets NF-κB). In this study, we investigated whether
Susan D Demo et al.
Cancer research, 67(13), 6383-6391 (2007-07-10)
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant toxicities have restricted the intensity of bortezomib dosing. Here we describe the antitumor activity of PR-171, a
Ver todos los artículos relacionados

Contenido relacionado

Protease Inhibitor Selection: Avoid Protein Loss in Sample Prep

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

Protease Inhibitor Selection: Avoid Protein Loss in Sample Prep

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

Protease Inhibitor Selection: Avoid Protein Loss in Sample Prep

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

Protease Inhibitor Selection: Avoid Protein Loss in Sample Prep

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico